Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2011-12-28 Regulatory Filings
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Axelar inleder fas II-studie av AXL1717 för behandling av icke-småcellig lungcancer
Regulatory Filings Classification · 1% confidence The document is a press release dated December 28, 2011, announcing that Axelar has dosed the first patient in a Phase II study for its drug candidate AXL1717 for non-small cell lung cancer. It details the study design, the drug's mechanism, and includes quotes from management. This type of announcement, detailing clinical trial progress and business updates, is characteristic of an Earnings Release (ER) if it were periodic results, or more generally, a corporate announcement. Since it is a specific, non-periodic announcement about a clinical trial milestone and business development, it fits best under the general category of an Earnings Release (ER) which often encompasses key operational and financial highlights, or potentially Regulatory Filings (RNS) if it were a mandatory filing. However, given the structure (headline, date, key announcement, management quotes, company background), it strongly resembles an Earnings Release (ER) or a general corporate update. Since 'ER' is defined as the 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical trial update, it is a significant corporate event announcement. In the absence of a specific 'Clinical Trial Update' code, and noting that it is a formal announcement of a major business event, it is closest to an Earnings Release (ER) in format, or RNS as a fallback. Given the focus on a major operational milestone (starting Phase II), ER is a strong candidate for corporate news dissemination, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate the definitions. It is not a 10-K, AR, CT, or IP. It is a press release announcing a major operational event. This is often categorized as an Earnings Release (ER) in broad databases, even if it's not strictly quarterly earnings, because it serves the same function of informing the market of key performance indicators/milestones. If it were purely a regulatory filing without the press release structure, RNS would be better. Given the structure, ER is plausible, but RNS (Regulatory Filings / General regulatory announcements) is the most appropriate catch-all for specific, non-periodic operational news releases that don't fit the other specific categories like DIV, CAP, or MANG. I will classify it as RNS as it is a general corporate announcement/press release not covered by a more specific code.
2011-12-28 Swedish
Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific corporate and clinical development event: the initiation of a Phase II clinical study for the drug candidate AXL1717. It contains key dates, company names (Axelar, Karolinska Development), details about the study design (randomized, comparison drug, endpoints), and quotes from management. This type of announcement, detailing operational progress, financing, or clinical milestones, is typically classified as a general corporate update or regulatory filing, but given the specific nature of clinical trial initiation, it fits best under the general 'Regulatory Filings' (RNS) category as it is not a formal financial report (10-K, IR, ER) or a specific management/governance document. It is an announcement of an operational event, which often falls into the RNS bucket when no other specific category applies. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Investor Presentation (IP). Since it is a news announcement, RNS is the most appropriate general regulatory filing category.
2011-12-28 English
Aprea meddelar fortsättning på klinisk fas I/II-studie av APR-246 i patienter med leukemi
Regulatory Filings Classification · 1% confidence The document is a press release from Aprea AB, dated December 12, 2011, announcing that the first patient has been dosed in a Phase I/II clinical study for their drug APR-246. It details the study's objectives (safety, pharmacokinetics, early efficacy), the patient population (AML and CLL), and the expected completion timeline (first half of 2012). This type of announcement, detailing clinical trial progress and key operational updates, is typically classified as a general Regulatory Filing (RNS) or sometimes an Investor Presentation (IP) if it were a slide deck. However, given the structure—a formal news announcement about a specific operational event (dosing a patient in a trial) rather than a comprehensive financial report (10-K, IR) or a management discussion (MDA)—the most appropriate category among the provided options is the general regulatory announcement fallback, RNS, as it is a formal notification to the market about a material development. It is not an Earnings Release (ER), which focuses on financial results, nor is it a specific management/board change (MANG).
2011-12-12 Swedish
Aprea announces continuation of clinical Phase I/II-study of APR-246 in patients with leukemia
Regulatory Filings Classification · 1% confidence The document is a press release dated December 12, 2011, announcing that the first patient has been dosed in a clinical Phase I/II-study for a compound called APR-246. It details the study's aims (safety, pharmacokinetics, effectiveness), the patient population (AML and CLL), and provides contact information and background on the companies involved (Aprea, Karolinska Development). This type of announcement, focusing on clinical trial progress and operational updates rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), fits best under the general category for corporate news that isn't strictly financial reporting or a specific regulatory filing like insider trading or dividend notices. Since it is a specific operational update that doesn't fit the other specialized codes (like DIV, DIRS, 10-K, ER), it is classified as a Regulatory Filing (RNS) as a broad category for corporate announcements, although 'LTR' (Legal Proceedings Report) is sometimes used for trial updates, RNS is the most appropriate general regulatory announcement fallback here, as it is not a formal legal proceeding report but a business/clinical update.
2011-12-12 English
Karolinska Development AB (publ) - Delårsrapport januari - september 2011
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the publication of an interim report (Delårsrapport) for the period January-September 2011. While it contains a summary table of financial data, the document explicitly states that the full report and presentation are available via external links at the end of the text. According to the 'Menu vs Meal' rule, since this is a short announcement (6511 characters) directing readers to the full report, it is classified as a Report Publication Announcement (RPA). 9M 2011
2011-11-25 Swedish
Karolinska Development AB (publ) - Interim report January - September 2011
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the publication of an interim report. While it contains a summary table of financial data, the text explicitly states 'announces publication of its Interim Report' and provides links to the full PDF report at the end. According to the 'Menu vs Meal' rule, documents that announce the availability of a report and provide links to it are classified as Report Publication Announcements (RPA). 9M 2011
2011-11-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.